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Dermatofibrosarcoma protuberans is an extremely rare, potentially malignant tumor type
that usually presents on the trunk or proximal extremities. The clinical presentation in-
cludes a gradually enlarging painless plaque-like or nodular lesion of the skin with
surrounding red to blue discoloration. The diagnosis is based on clinical presentation,
computed tomography or magnetic resonance imaging, and biopsy with histologic anal-
ysis. An early and timely diagnosis improves chances of complete surgical resection thus
improving prognosis. Herein, we present a rare case of dermatofibrosarcoma protuberans
with the hopes that its addition to the literature will aid in the earlier recognition of future
patients and help prevent this potentially curable disease from becoming deadly.
Copyright © 2016, the Authors. Published by Elsevier Inc. under copyright license from the
University of Washington. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Dermatofibrosarcoma protuberans (DFSP) accounts for
approximately 1%-6% of all soft-tissue tumors [1,2]. It has an
annual incidence of 4.2 per million [3]. Although there have
not been many extensive studies performed that identify the
differences in the incidence of DFSP across race and sex,
preliminary data points toward DFSP being approximately
twice as common in blacks as compared with whites and
equally distributed betweenmales and females [3]. The tumor
is found to be located on the trunk in 40%-50% of cases, the
chest and shoulders in 30%-40% of cases, and the proximal
portion of the limbs in 10%-15% of cases. Some studies reportlared that no competing i
C. Wales).
blished by Elsevier Inc. u
ND license (http://creativa greater frequency of distally located DFSP in children. One
study of 27 cases, reports that 14.8% of childhood DFSP was
located on the hands or feet [4]. It presents most frequently
between the ages of 20 and 50 years [1]. Clinicians should be
made aware that DFSP is known to occur among children.
Because it occurs less commonly in this patient population, it
is frequently misdiagnosed or underdiagnosed.Case report
A 14-year-old boy with a history of a soft-tissue mass on the
dorsum of his left foot since age 5 presented to the hospitalnterests exist.
nder copyright license from the University of Washington. This is
ecommons.org/licenses/by-nc-nd/4.0/).
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the last 3 months, see Figure 1. During the same period, the
mass began eluting a serous fluid through separated skin
margins over the 2nd and 3rd toes. He had developed areas of
skin loss on the lateral aspect of the foot overlaying the 5th
metatarsal and the anterolateral aspect of his ankle in an
approximately vascular distribution. Physical examination
confirmed a large ulcerating mass over the dorsum of the left
foot with decreased sensation of the overlying skin. Magnetic
resonance imaging (MRI) confirmed a 10  15  18-cm ovoid
mass on the dorsum of the left foot, see Figure 2. Incisional
biopsy results were consistent with DFSP, see Figure 3. After
the biopsy results, surgical removal of the lesion was carried
out to remove the locally invasive tumor.Discussion
DFSP is a fibrohistiocytic tumor of intermediate malignancy
characterized by a nodular cutaneous mass. It is most
frequently located on the trunk and proximal extremities and
has a propensity for recurrence. Because of its indolent
growth, it is hypothesized that these tumors frequently arise
during childhood but only become apparent during young
adulthood [5]. Giant cell fibroblastoma (GCF) is considered to
be the juvenile form of DFSP [1]. Initially, it manifest as a firm,
plaque-like lesion of the skin with surrounding red to blue
discoloration. Rarely, these tumors present as an area of at-
rophy or small subcutaneous nodules rather than a plaque [5].Fig. 1 e A large fungating mass present preoperatively on
the left foot of a 14-year-old boy.Prior trauma is reported in up to 20% of cases and larger le-
sions can ulcerate, bleed, and become painful.
The tumor is characterized histologically by surface bound
CD34 and the absence of factor XIIIa, which are used to
differentiate it from other soft-tissue tumors [6]. Molecular
characterization of DFSP has identified an associationwith the
chromosomal translocation t(17;22)(q22;q13) and with super-
numerary ring chromosomes containing material from chro-
mosomal regions 17q22 and 22q13 accompanied by simple
chromosome trisomies. These genetic aberrations fuse the
COL1A1 and PDGF beta genes, resulting in PDGF beta being
under the transcriptional control of theCOL1A1promoter. This
gives rise to anoverexpression of PDGFbeta,which leads to the
constitutive activation of the platelet-derived growth factor
subunit B (PDGFB) receptor, a type III tyrosine kinase receptor
leading to autocrine stimulation and tumorigenesis [1,7,8].
Multiple histologic variants of DFSP exist. These variants
include myxoid DFSP, the Bednar tumor, the atrophic variant
of DFSP, and GCF. The myxoid variant is characterized by the
presence of moderately cellular areas made up of stellate or
fusiform cells with abundant accumulation of hyaluronidase-
sensitive mucin in the intercellular space. The Bednar tumor
has a pigmented storiform appearance. The atrophic variant
of DFSP is characterized by reduced thickness of the dermis
and replacement of much of the dermis and subcutis by
spindle cells. Finally, the GCF is often myxoid and punctuated
by pseudovascular tissue spaces being lined by multinucle-
ated giant cells [1].
Presumptive diagnosis of DFSP can usually be made based
on clinical appearance alone do to its superficial location and
characteristic findings. However, the ease of diagnosis of less
superficial tumors can be enhanced through the use of im-
aging techniques. The radiologic appearance of DFSP is char-
acterized by a nodular soft-tissue mass involving the skin and
subcutaneous adipose tissue with a lack of mineralization [9].
The case we present here provides unique radiologic images
that can be used as comparisons for physicians that are
treating patients with potential DFSP.
Both computed tomography (CT) and MRI can be used to
define the underlying structure of a given lesion. In 1 study of
14 cases, CT generatedminimally enhanced images in 3 of the
cases, heterogeneously enhanced images in another 3 cases,
and homogenously enhanced images in 8 cases. In the same
study, all 14 lesions imaged with MRI were T1-isointense to
muscle. Ten lesions were T2-hyperintense and 4 were T2-
isointense to T2-hypointense to muscle. T1 postcontrast
enhancement patterns ranged from mild to markedly het-
erogeneous or markedly homogeneous [10].
MRI has stood out as the modality of choice for margin
definition in planned operative procedures for DFSP because
of the increased resolution available with higher Tesla (3-4T)
magnets as compared with CT. MRI also surpasses CT in its
utility for imaging DFSP because of the ability to produce im-
ages with unique imaging protocols: T1, T2, frequency-
selective fat suppression, and short tau inversion recovery
(STIR). DFSPs are usually hypointense to fat on T1-weighted
images and hyperintense to isointense to fat on T2-weighted
images. Specialized techniques such as frequency-selective
fat suppression and STIR are frequently used to accentuate
the pathology on MRI [11].
Fig. 2 eMagnetic resonance imaging findings of the DFSP of the foot in a 14-year-old boy. (Left) Sagittal fast spin echo (FSE)
T2-weighted fat suppressed (FS) image shows a large, lobulated mass in the dorsum of the foot with mildly heterogeneous,
hyperintense signal intensity. The mass involves the dermis and subcutaneous soft tissues, without osseous invasion or
scalloping. (Middle and right) Axial (middle) and sagittal (right) enhanced T1-weighted FS images show marked
enhancement of the lobulated mass, without involvement of the metatarsals.
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using a pulse of radio waves at the resonant frequency of
protons contained in fat. This dephases the protons, resulting
in a decreased signal intensity of fat, thus accentuating the
DFSP. STIR is an inversion recovery pulse sequence timed to
decrease the signal intensity of fat. It works by first generating
a radio frequency pulse that inverts the spin of protons from
all tissue types, then, when fat has reached its null point and
there is no fat magnetization to flip into the x-y plane, the
image is taken. Using these techniques, MRI has been found to
be useful in identifying atypical cases, the extent of tumorFig. 3 e Upper left: hematoxylin-eosin stain of the epidermis, der
hematoxylin-eosin stain of classic storiform pattern of fibrohist
left: hematoxylin-eosin stain of mitotic bodies present within th
lesion (10£).spread, and determining depth and involvement of critical
structures. The use of MRI is now suggested in DFSP for the
following situations: large tumor size, tumors with a sus-
pected deeper component, recurrent tumors, critical
anatomic locations, and reexcision of DFSPs with positive
surgical margins [11].
The final 2 imaging modalities that are used for patients
with DFSP are arteriography and bone scintigraphy. Arteri-
ography will demonstrate minor to moderate hyper-
vascularity of the tumor. Bone scintigraphy will demonstrate
increased accumulation of radiopharmaceutical [9].mis, and subcuticular region of the lesion (4£). Upper right:
iocytic tumors found within this patient's DFSP (4£). Lower
is patients lesion (40£). Lower right: CD34þ staining of the
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DFSP. The fusion of COL1A1 and PDGF beta results in the
overexpression of PDGF beta which leads to the constitutive
activation of the PDGFB receptor, a type III tyrosine kinase
receptor. PDGFB receptor has intracellular tyrosine kinase
activity that functions through the PI3 kinase and Ras-
mitogen-activated protein kinase pathways. Activation of
these pathways controls cellular proliferation, adhesion,
and apoptosis [1,12]. The discovery of this mechanism of
action led to the suggestion that tyrosine kinase inhibitors
such as imatinib may have a role to play in therapy for DFSP.
Resulting studies demonstrated that doses between 400 and
800 mg daily for a period ranging from 2 to 24 months pro-
duced an average tumor reduction of 50% after a median
follow-up time of 24 months [1].
For locally invasive DFSP, a surgical approach of wide
excision with margins of 2-3 cm is standard practice [13].
However, frequent local recurrence of approximately 20%
with these margins and unacceptable cosmetic defects with
wider margins has led to the search for a technique that more
confidently produces negative surgical margins [1]. This
increased frequency of local recurrence is thought to be a
result of increased production of hyaluronic acid leading to
increased invasion of surrounding tissue by tumor micro-
tendrils [14]. As a result, Mohs micrographic surgery (MMS) is
becoming a more and more common means of tumor resec-
tion, both for its more accurate production of clear margins,
<1%, and its preservation of nondiseased tissue. The tech-
nique used differs slightly from normal MMS in that the tissue
is fixed in formalin and then embedded in paraffin. This
method facilitates the diagnosis of fat invasion by the tumor
that could otherwise go unnoticed in frozen sections [1,14].
Surgical resection using the modified MMS technique is
carried out by first debulking the main portion of the tumor
mass. Then 0.5 to 1.0-cm margins of tissue are removed from
what remains. This excised tissue is then formalin fixed and
paraffin embedded. Finally, it is hematoxylin and eosin
stained and confirmed with CD34 immunostaining [14].
Radiotherapy has been used in the treatment of DFSP pri-
marily as an adjuvant to surgery and chemotherapy in in-
stances where there is a high probability that the lesion was
not completely removed through surgery [1]. In one study, a
radiation dose of between 50 and 80 gray, depending on
whether radiation therapy alone was used or radiation in
combinationwith surgical resection was used, generated a 10-
year local control rate of 88% for the 18 patients studied [15].
Radiation therapy remains a viable option as the sole treat-
ment of nonresectable tumors and in the presence of resected
tumors with positive or negative margins to ensure complete
removal of all potentially cancerous tissue.Conclusions
As we have established, DFSP is a very rare but potentially
malignant soft-tissue tumor. A timely diagnosis can signifi-
cantly decrease patient morbidity and mortality and is
therefore critical. Clinicians should be aware that DFSP can
occur in the pediatric population and should understand thedifferences in presentation that accompany the childhood
form of the disease. We hope that this case will serve as a
reference for physicians presented with similar cases of soft-
tissue masses in both the adult and pediatric population.r e f e r e n c e s
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